Bureau of Narcotic Enforcement

The Bureau of Narcotic Enforcement (BNE) is responsible for protecting the public health by combating the illegal use and trafficking of prescription controlled substances. The Bureau provides millions of secure Official New York State Prescriptions annually to over 95,000 prescribing practitioners across the State. BNE monitors and regulates controlled substances through its issuance of licenses to manufacturers, distributors, hospitals, nursing homes, and researchers. BNE Narcotic Investigators investigate suspected drug diversion or illegal sales involving theft, forgery, and fraudulent visits to practitioners' offices, and work closely with local, state and federal law enforcement. The Bureau also prevents prescription drug abuse through educational materials and presentations for parents, educators, and healthcare professionals.

Opioid Stewardship Act

Effective July 1, 2018, all manufacturers, distributors, and importers licensed in New York State (NYS) as of January 1, 2017, must report transaction information for all opioids sold or distributed to or within NYS to the NYS Department of Health's Bureau of Narcotic Enforcement as mandated under the Opioid Stewardship Act (OSA). The Department will calculate ratable shares of an assessment based on the reported data, and will issue invoices for the ratable shares of the assessment to each licensee by October 15, 2018. Payments of the invoices are due on January 1, 2019. The Department will provide guidance on when subsequent reports and payments are due for future years.

Click on the following links for more information and guidance.